Related Experiment Video
Updated: Jan 27, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Tridecaptin M, a New Variant Discovered in Mud Bacterium, Shows Activity against Colistin- and Extremely
Manoj Jangra1, Manpreet Kaur1, Rushikesh Tambat1
1Clinical Microbiology and Bioactive Screening Laboratory, CSIR-Institute of Microbial Technology, Chandigarh, India.
Abstract:
The World Health Organization has categorized the Gram-negative superbugs, which are inherently impervious to many antibiotics, as critical priority pathogens due to the lack of effective treatments. The breach in our last-resort antibiotic (i.e., colistin) by extensively drug-resistant and pan-drug-resistant Enterobacteriaceae strains demands the immediate development of new therapies. In the present study, we report the discovery of tridecaptin M, a new addition to the family, and its potential against colistin-resistant Enterobacteriaceae in vitro and in vivo Also, we performed mode-of-action studies using various fluorescent probes and studied the hemolytic activity and mammalian cytotoxicity in two cell lines. Tridecaptin M displayed strong antibacterial activity (MICs of 2 to 8 μg ml-1) against clinical strains of Klebsiella pneumoniae (which were resistant to colistin, carbapenems, third- and fourth-generation cephalosporins, fluoroquinolones, fosfomycin, and other antibiotics) and mcr-1-positive Escherichia coli strains. Unlike polymyxins, tridecaptin M did not permeabilize the outer membrane or cytoplasmic membrane. It blocked ATP synthesis in bacteria by dissipating the proton motive force. The compound exhibited negligible acquired resistance, low in vitro cytotoxicity and hemolytic activity, and no significant acute toxicity in mice. It also showed promising efficacy in a thigh infection model of colistin-resistant K. pneumoniae Altogether, these results demonstrate the future prospects of this class of antibiotics to address the unmet medical need to circumvent colistin resistance in extensively drug-resistant Enterobacteriaceae infections. The work also emphasizes the importance of natural products in our shrunken drug discovery pipeline.
Insights
A new antibiotic, tridecaptin M, shows potent activity against critical Gram-negative superbugs resistant to last-resort drugs like colistin. It offers a novel mechanism by blocking bacterial ATP synthesis with low toxicity, addressing urgent treatment needs.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Gram-negative superbugs are critical priority pathogens due to antibiotic resistance.
- Existing last-resort antibiotics like colistin are losing efficacy against extensively drug-resistant and pan-drug-resistant Enterobacteriaceae.
- There is an urgent need for novel therapeutic strategies to combat multidrug-resistant bacterial infections.
Purpose of the Study:
- To report the discovery of tridecaptin M, a novel antibiotic.
- To evaluate the efficacy of tridecaptin M against colistin-resistant Enterobacteriaceae in vitro and in vivo.
- To investigate the mechanism of action, cytotoxicity, and safety profile of tridecaptin M.
Main Methods:
- Antibacterial activity was assessed using minimum inhibitory concentrations (MICs) against clinical strains.
- Mode-of-action studies employed fluorescent probes to analyze membrane permeability and proton motive force.
- Cytotoxicity and hemolytic activity were evaluated in cell lines, and in vivo toxicity was assessed in mice.
- Efficacy was tested in a murine thigh infection model.
Main Results:
- Tridecaptin M demonstrated potent activity (MICs 2-8 μg/mL) against colistin-resistant Klebsiella pneumoniae and mcr-1-positive Escherichia coli.
- Unlike polymyxins, tridecaptin M inhibits bacterial ATP synthesis by dissipating proton motive force, without outer or cytoplasmic membrane permeabilization.
- The compound exhibited negligible acquired resistance, low in vitro cytotoxicity and hemolytic activity, and no significant acute toxicity in mice.
- Promising efficacy was observed in a mouse model of colistin-resistant K. pneumoniae thigh infection.
Conclusions:
- Tridecaptin M represents a promising new class of antibiotics effective against challenging Gram-negative superbugs.
- Its novel mechanism of action and favorable safety profile offer a potential solution to circumvent colistin resistance.
- Natural products remain a vital resource for antibiotic discovery to address the critical unmet medical need for new therapies.
Related Concept Videos
Histone Variants at the Centromere
Absolute and Local Extreme Values
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Resistivity

